BioMarin Pharmaceutical | BMRN - 应收帐款人



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 12.6B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


应收帐款人 更改 日
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amgen USD 10.23B 1.09B 2026-06
Bayer EUR 18.7B 146M 2026-06
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
Incyte USD 1.13B 73.7M 2026-06
Insmed USD 215.32M 36.77M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Moderna USD 17M 54M 2026-06
Neurocrine Biosciences USD 887M 118.9M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 482M 85M 2026-03
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
United Therapeutics USD 310.3M 1.7M 2026-06
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06